Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
30
VATE Quote, Financials, Valuation and Earnings
Last price:
$5.77
Seasonality move
:
-13.9%
Day range:
$5.42 - $5.90
52-week range:
$3.25 - $13.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.07x
P/B ratio:
--
Volume:
8.2K
Avg. volume:
18.3K
1-year change:
-11.75%
Market cap:
$69.9M
Revenue:
$1.1B
EPS (TTM):
-$3.36
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Innovate has 850.57% upside to fair value with a price target of -- per share.
VATE vs. S&P 500
-
Over the past 5 trading days, Innovate has underperformed the S&P 500 by -7.45% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Innovate does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Innovate revenues have been falling on a year-over-year basis for 9 quarters in a row. In the most recent quarter Innovate reported revenues of $274.2M.
Earnings Growth
-
Innovate has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Innovate reported earnings per share of -$1.89.
Enterprise value:
719.2M
EV / Invested capital:
--
Price / LTM sales:
0.07x
EV / EBIT:
17.04x
EV / Revenue:
0.67x
PEG ratio (5yr expected):
-0.09x
EV / Free cash flow:
312.68x
Price / Operating cash flow:
30.59x
Enterprise value / EBITDA:
9.64x
Gross Profit (TTM):
$205.7M
Return On Assets:
-4.64%
Net Income Margin (TTM):
-3.91%
Return On Equity:
--
Return On Invested Capital:
-8.03%
Operating Margin:
1.24%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $1.5B | $1.4B | $1.1B | $315.2M | $274.2M | |
| Gross Profit | $215.2M | $221M | $205.7M | $48.6M | $45.5M | |
| Operating Income | $8.7M | $33.3M | $40.6M | $2.8M | $3.4M | |
| EBITDA | $61.1M | $59.9M | $74.6M | $8.8M | $9.4M | |
| Diluted EPS | -$4.87 | -$5.66 | -$3.36 | -$2.21 | -$1.89 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $5.9B | $476.6M | $487.9M | $429.2M | $372.1M | |
| Total Assets | $6.4B | $1.1B | $1B | $943.5M | $868M | |
| Current Liabilities | $5.5B | $441.5M | $374.5M | $349M | $847.6M | |
| Total Liabilities | $6B | $1.1B | $1.2B | $1.1B | $1.1B | |
| Total Equity | $413.5M | -$21.6M | -$123.3M | -$174.4M | -$185M | |
| Total Debt | $546.1M | $681.1M | $697.2M | $675.7M | $663.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$23.1M | $78.1M | $20.4M | -$25.4M | -$14.1M | |
| Cash From Investing | $36.1M | -$15.4M | -$14.5M | -$3.3M | -$3.9M | |
| Cash From Financing | -$21.1M | -$40.2M | -$11.2M | -$12.9M | $2.4M | |
| Free Cash Flow | -$42.9M | $57.8M | $2.3M | -$31M | -$18.8M | |
VATE
Sector
Market Cap
$69.9M
$611.3M
Price % of 52-Week High
38.14%
81.21%
Dividend Yield
0%
0%
Shareholder Yield
--
2.28%
1-Year Price Total Return
-16.53%
-1.12%
Beta (5-Year)
1.718
0.761
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
-2.88%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$5.48
200-day SMA
Sell
Level
$6.56
Bollinger Bands (100)
Sell
Level
5.21 - 8.01
Chaikin Money Flow
Sell
Level
-1.6K
20-day SMA
Buy
Level
$5.37
Relative Strength Index (RSI14)
Buy
Level
51.17
ADX Line
Buy
Level
23.5
Williams %R
Neutral
Level
-69.5604
50-day SMA
Sell
Level
$5.75
MACD (12, 26)
Buy
Level
1.51
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
51.4K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.4878)
Sell
CA Score
(Annual)
Level (-2.9405)
Sell
Beneish M-Score
(Annual)
Level (-1.888)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (5.1429)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Sell
Fundamental Score
Level (0)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.
Stock Forecast FAQ
In the current month, VATE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The VATE average analyst price target in the past 3 months is --.
-
Where Will Innovate Stock Be In 1 Year?
According to analysts, the consensus estimate is that Innovate share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Innovate?
Analysts are divided on their view about Innovate share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Innovate is a Sell and believe this share price will drop from its current level to --.
-
What Is Innovate's Price Target?
The price target for Innovate over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is VATE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Innovate is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of VATE?
You can purchase shares of Innovate via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Innovate shares.
-
What Is The Innovate Share Price Today?
Innovate was last trading at $5.77 per share. This represents the most recent stock quote for Innovate. Yesterday, Innovate closed at $5.56 per share.
-
How To Buy Innovate Stock Online?
In order to purchase Innovate stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 18
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
